A major Korro Bio shareholder bought $2.3M in stock on March 10, boosting their stake by nearly 19%, despite the company's poor quarterly results.

On March 10, 2026, a major shareholder of Korro Bio (KRRO) purchased 207,100 shares at $11.11 each, spending about $2.3 million and increasing their stake by 18.99% to 1.3 million shares. The transaction, disclosed in an SEC filing, occurred as the company reported a quarterly loss of $5.32 per share on $1.29 million in revenue, significantly worse than expected. Despite weak financial results, the insider buy signaled confidence. The stock closed at $11.50 on March 13, down $0.26, with a market cap of $108.33 million and a negative P/E ratio. Analysts hold a "Hold" consensus rating with a $50.38 average target.